Popular on eTradeWire
- Rosenberg Fans Canada Ltd. will be exhibiting at CIPHEX WEST- 2018 in Calgary 513
- Chelsea Village Selects Corner Property Management for Upscale Residences in Bridgewater Township NJ 290
- Jason McIntosh--Apartment Association of Metro Denver Executive of the Year Finalist 290
- Actress & Musician Linda Collins Uses Diverse Entertainment Background to Bring Unique Edge to Roles 288
- Sophia King, Award-winning Atlanta Author, Showcasing At Miami Book Fair November 17 and 18 275
- Space Continuum LLC, Wins Contract from Obama Foundation 266
- Newport Digital Marketing for Solicitors | Newport Solicitor SEO 195
- Dr. Noam Arzt named Fellow of the American Medical Informatics Association 168
- "Wicked Twisted Road": An Interview With Reckless Kelly 161
- ASA Appraisal Courses at Massachusetts College of Art and Design 159
Similar on eTradeWire
- Acetylcholinesterase Inhibitor Screening Kit (Colorimetric)
- New Findings on The Same Driver Gene Mutation Exists in All Metastatic Tumors
- For Injectable Drugs Wireless Connectivity Allows Caregivers to Manage Patients by Exception Basis
- Research Article Cites Cleanascite™ To Study Diabetic Regulation
- PicoProbe™ Glycerol-3-Phosphate Assay Kit (Fluorometric)
- Sorbitol Dehydrogenase Activity Assay Kit (Colorimetric)
- Stemology® Continues its Quest for Younger Looking Skin
- PicoProbe™ Glutamate Assay Kit (Fluorometric)
- DNAtix Releases Live Demo of its Blockchain based Genetic Infrastructure Platform
- Creative Peptides Recently Launches Peptide Modification Services for Science Community
Rupali Verma, the principal analyst, stated, "Close to 45% of the subcutaneously administrable biologics are monoclonal antibodies; these are followed by other types of protein-based therapeutics, including interferons, interleukins, hormones, enzymes and cytokines. Further, even certain vaccines, recombinant peptides and cell / gene therapies are other therapy types being evaluated for subcutaneous delivery. Moreover, ongoing technical advances have led to the development of innovative technology platforms designed to enable the delivery of highly viscous formulations as well."
The report presents opinions on several key aspects of the market. Among other elements, it includes:
1. A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, along with information on the developer(s), type of molecule, target indication / therapeutic area, approval year, dose strength, treatment regimen and available dosage forms. The study also includes comprehensive case studies on leading subcutaneous biologics, featuring details on annual sales, mechanisms of action, development histories, technology platforms (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
2. An in-depth analysis of the various subcutaneous biologics that are currently under clinical development, with information on the developer(s), phase of development, type of molecule, and target therapeutic area.
3. A review of various innovative technology platforms that are used for the formulation of drugs for subcutaneous delivery, highlighting their key features and providing information on their developers, mechanisms of action and advantages. The study also includes an insightful three-dimensional analysis of the technology platforms that are presently engaged in developing drug formulations for subcutaneous delivery, comparing them based on pipeline strength (in terms of marketed / under development drugs based on the technology), supplier power (in terms of year of establishment and size of employee base) of the developer and a number of collaborations established related to the technology.
More on eTradeWire News
- College of Business Administration Named a "Best" Business School by Princeton Review
- Domestic violence victims offered life-saving loans
- CSS Inc. Ranks for the Third Time on HRO Today's Baker's Dozen for Pre-Employment Screening
- Trumped — an Alternative Musical Bids to Make Theatre Great Ag
- New President & Chief Executive Officer selected to lead NGL
- Lehigh Acres Middle School to showcase innovative programs, culture of success at open house Dec. 13
- Leadership Award Winner Samer Khouli of TargetcCW
4. A detailed benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.
5. Elaborate profiles of key technology providers, featuring an overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations) and a comprehensive future outlook.
6. In-depth review of the most advanced and popular subcutaneous drug delivery systems, focused on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants, providing information on their developer(s) and device specifications / features. Details of specific parameters captured for different device categories are mentioned as follows:
7. Large volume wearable injectors: Type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and stage of development (commercialized and under development).
8. Autoinjectors: Type of drug container (syringe, cartridge and others), usability (disposable and reusable), mechanism of action (automatic, semi-automatic and manual), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
9. Pen injectors: Usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
10. Needle free injection systems: Type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered (in mL).
11. Prefilled syringes: Type of syringe (glass and plastic).
12. Drug reconstitution systems: Type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable).
13. Implants: Type of material (silicone, titanium, polymers and others), target therapeutic indication, type of implant (biodegradable and non-biodegradable), treatment duration, type of drug delivered, dose strength and stage of development.
More on eTradeWire News
- Federal Employee Benefits TV Series Part 13 Topic: Updates on the 2019 Health Insurance
- Five Way Foods Partners with Stonewall Kitchen for Ready-to-Use Soup Mixes
- Rainbow Village's "We Are Family" Benefit Gala 2018 Proves Major Success
- Thorofare Capital Funds $36 Million Loan to Refinance Dallas, TX Office Complex
- Thanksgiving Week Brings Holiday Cheer, Major Savings at The Abbey Resort
- Fine art, estate jewelry, decorative art will come up for bid December 5th at Gray's in Cleveland
- Closets For Life Wins CotY Award for 6th Year
14. A comprehensive product competitiveness analysis of large volume wearable injectors and subcutaneous autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall subcutaneous products market.
Verma further added, "Despite the various limitations associated with subcutaneous formulations, the field offers immense opportunities to pharmaceutical companies, device manufacturers and technology developers. Companies are also reformulating their intravenous drugs for subcutaneous administration for life cycle management and product differentiation purposes. The rising incidence of chronic clinical conditions (which are characterized by the need for frequent administration of medications) and continuous efforts of therapy / device developers in this field are anticipated to drive the growth in this market in the coming years."
The research covers detailed profiles and assesses product portfolios of the following companies:
2. Ajinomoto Althea
4. Ascendis Pharma
5. Avadel Pharmaceuticals
7. Halozyme Therapeutics
9. Xeris Pharmaceuticals
10. Serina Therapeutics
For additional details, please visit
or email firstname.lastname@example.org
- Doubletake Named Agency of Record for First Airline Monument Project
- 8 Gifts for Hanukkah That will Light up Your Pet's Life
- Anthem Ranch by Toll Brothers offers last chance to live in this community
- Hollywood Author Josh Hickman Releases Latest Fantasy Book "The Kinfolk: The Cult of Sex and Cheese"
- NovaPoint Capital Named Top Guns Manager by Informa Investment Solutions
- Buying Domains and Hosting for Promotional Purposes
- No dust to settle - Degafloor new dust free filler
- Bespoke Commercial Real Estate Celebrates Five Years of Growth and Service
- Registration opens for the 4th annual Future Armoured Vehicles Situational Awareness conference
- Questions To Ask A Homecare Agency To Determine The Right Fit
- 15th Annual Candlelight Service of Remembrance Celebration Scheduled for Dec. 2, 2018
- RadiusPoint Identifies Half A Million Dollar Overcharge for Client!
- Matanzas Craft Beer Fest on the Bay raises $3,500 for Operation Open Arms
- Terri Russell joins Stevens Construction Inc
- Dress for Success Worldwide's #DFSPowerPiece Campaign for Giving Tuesday
- St Mary Mother of the Church 23rd Annual Chirstmas Concert
- Fantasy Gift 1946 Indian Chief Motorcycle Debuts At Highland Park Village, Dallas
- Sandi Anne Borowsky Releases New Beatles Book and Schedules Appearances
- Stockport Homes Group awards asbestos consultancy contract to Airborne Environmental Consultan
- The Bone Woman on Talk Story Today